Steven Kyle Boyd Acquires 25,000 Shares of OraSure Technologies (NASDAQ:OSUR) Stock

OraSure Technologies, Inc. (NASDAQ:OSUR) Director Steven Kyle Boyd acquired 25,000 shares of the firm’s stock in a transaction on Tuesday, May 12th. The stock was purchased at an average price of $2.98 per share, with a total value of $74,500.00. Following the transaction, the director owned 63,462 shares of the company’s stock, valued at approximately $189,116.76. This trade represents a 65.00% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

Steven Kyle Boyd also recently made the following trade(s):

• On Thursday, May 14th, Steven Kyle Boyd acquired 25,000 shares of OraSure Technologies stock. The stock was purchased at an average price of $2.99 per share, with a total value of $74,750.00.

OraSure Technologies Stock Performance

Shares of OraSure Technologies stock opened at $3.00 on Friday. The firm has a 50-day simple moving average of $3.06 and a two-hundred day simple moving average of $2.76. The company has a market cap of $206.55 million, a P/E ratio of -2.88 and a beta of 0.89. OraSure Technologies, Inc. has a fifty-two week low of $2.08 and a fifty-two week high of $3.82.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings data on Wednesday, February 25th. The medical instruments supplier reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). The firm had revenue of $26.76 million during the quarter, compared to analyst estimates of $26.44 million. OraSure Technologies had a negative return on equity of 18.57% and a negative net margin of 66.42%.

Institutional Trading of OraSure Technologies

Institutional investors and hedge funds have recently modified their holdings of the stock. Prudential Financial Inc. purchased a new stake in OraSure Technologies during the 2nd quarter valued at about $31,000. Quadrature Capital Ltd purchased a new stake in OraSure Technologies during the 4th quarter valued at about $28,000. Diversify Wealth Management LLC purchased a new stake in OraSure Technologies during the 1st quarter valued at about $36,000. Amundi purchased a new stake in OraSure Technologies during the 1st quarter valued at about $47,000. Finally, BNP Paribas Financial Markets grew its stake in OraSure Technologies by 102.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,275 shares of the medical instruments supplier’s stock valued at $49,000 after acquiring an additional 7,720 shares in the last quarter. Hedge funds and other institutional investors own 93.50% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of OraSure Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, May 7th. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, OraSure Technologies has an average rating of “Reduce” and a consensus target price of $3.00.

About OraSure Technologies

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.